Abstract
Reverse transcriptase (RT) is one of the most important targets for HIV drug discovery. However, the emergence of resistant mutants has become one of the biggest challenges in HIV-1 RT drug discovery/development and attracted great research interests worldwide. It is particularly important to develop novel anti-HIV-1 RT agents that have improved potency and efficacy against the wild-type (WT) RT, but also target resistant RT forms. Previous crystal complex structures of HIV-1 RT revealed the interaction mechanism between the enzyme and inhibitors, which promoted the exploitation of inhibitor that had sufficient conformational flexibility to combat resistance. Hence, the potential flexibility of a drug should be part of the strategy considered in the early stages of designing drugs that are intended to be broadly effective against mutated targets associated with drug resistance. This review provides an overview of the state of the art in this field, including design strategies and challenges for medicinal chemists.
Keywords: HIV Reverse transcriptase, conformational flexibility, drug resistance.
Current Pharmaceutical Design
Title:Structure-based Design of Conformationally Flexible Reverse Transcriptase Inhibitors to Combat Resistant HIV
Volume: 20 Issue: 5
Author(s): Ge-Fei Hao, Sheng-Gang Yang and Guang-Fu Yang
Affiliation:
Keywords: HIV Reverse transcriptase, conformational flexibility, drug resistance.
Abstract: Reverse transcriptase (RT) is one of the most important targets for HIV drug discovery. However, the emergence of resistant mutants has become one of the biggest challenges in HIV-1 RT drug discovery/development and attracted great research interests worldwide. It is particularly important to develop novel anti-HIV-1 RT agents that have improved potency and efficacy against the wild-type (WT) RT, but also target resistant RT forms. Previous crystal complex structures of HIV-1 RT revealed the interaction mechanism between the enzyme and inhibitors, which promoted the exploitation of inhibitor that had sufficient conformational flexibility to combat resistance. Hence, the potential flexibility of a drug should be part of the strategy considered in the early stages of designing drugs that are intended to be broadly effective against mutated targets associated with drug resistance. This review provides an overview of the state of the art in this field, including design strategies and challenges for medicinal chemists.
Export Options
About this article
Cite this article as:
Hao Ge-Fei, Yang Sheng-Gang and Yang Guang-Fu, Structure-based Design of Conformationally Flexible Reverse Transcriptase Inhibitors to Combat Resistant HIV, Current Pharmaceutical Design 2014; 20 (5) . https://dx.doi.org/10.2174/138161282005140214163439
DOI https://dx.doi.org/10.2174/138161282005140214163439 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STAT Signaling and Cell Function
Current Genomics DprE1 - from the Discovery to the Promising Tuberculosis Drug Target
Current Pharmaceutical Design An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Polysaccharide-Based Nanobiomaterials as Controlled Release Systems for Tissue Engineering Applications
Current Pharmaceutical Design How Do Microbubbles and Ultrasound Interact? Basic Physical, Dynamic and Engineering Principles
Current Pharmaceutical Design Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Potential Approaches to Enhance the Effects of Estrogen on Senescent Blood Vessels and Postmenopausal Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Aptamers and New Bioreceptors for the Electrochemical Detection of Biomarkers Expressed in Hepatocellular Carcinoma
Current Medicinal Chemistry Diagnosis and Possible Use of Traditional Medicinal Plant to combat COVID-19
Coronaviruses Five Years Patenting Time Frame Concerning Enzymatic Preparation of Glycosides
Recent Patents on Biotechnology Synthesis of Celecoxib and Structural Analogs- A Review
Current Organic Chemistry Novel Vitreous Modulators for Pharmacologic Vitreolysis in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders The Rb Pathway and Cancer Therapeutics
Current Drug Targets p53 Directly Regulates αA- and βA3/A1-Crystallin Genes to Modulate Lens Differentiation
Current Molecular Medicine Somatic Genome Variations in Health and Disease
Current Genomics